scispace - formally typeset
M

Margi Sheth

Researcher at National Institutes of Health

Publications -  34
Citations -  77059

Margi Sheth is an academic researcher from National Institutes of Health. The author has contributed to research in topics: DNA methylation & Gene. The author has an hindex of 32, co-authored 34 publications receiving 61560 citations.

Papers
More filters
Journal ArticleDOI

Comprehensivemolecular characterization of clear cell renal cell carcinoma

Chad J. Creighton, +291 more
- 28 Aug 2013 - 
TL;DR: Remodelling cellular metabolism constitutes a recurrent pattern in ccRCC that correlates with tumour stage and severity and offers new views on the opportunities for disease treatment.

Integrated genomic characterization of endometrial carcinoma

Gad Getz, +271 more
TL;DR: The genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours, and these features are classified into four categories: POLE ultramutated, microsatellite instability hypermutated, copy- number low, and copy-number high.
Journal ArticleDOI

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Daniel J. Brat, +306 more
TL;DR: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class.
Journal ArticleDOI

Genomic Classification of Cutaneous Melanoma

Rehan Akbani, +351 more
- 18 Jun 2015 - 
TL;DR: This clinicopathological and multi-dimensional analysis suggests that the prognosis of melanoma patients with regional metastases is influenced by tumor stroma immunobiology, offering insights to further personalize therapeutic decision-making.
Journal ArticleDOI

Comprehensive molecular characterization of urothelial bladder carcinoma

John N. Weinstein, +296 more
- 01 Jan 2014 - 
TL;DR: Ch Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities.